Identification

Name
Amperozide
Accession Number
DB08927
Type
Small Molecule
Groups
Experimental
Description

Amperozide is an atypical antipsychotic of the diphenylbutylpiperazine class which acts as an antagonist at the 5-HT2A receptor. It does not block dopamine receptors as with most antipsychotic drugs, but does inhibit dopamine release, and alters the firing pattern of dopaminergic neurons. It was investigated for the treatment of schizophrenia in humans, but never adopted clinically, its main use is instead in veterinary medicine, primarily in intensively farmed pigs, for decreasing aggression and stress and thereby increasing feeding and productivity. [Wikipedia]

Structure
Thumb
Synonyms
Not Available
Categories
UNII
0M2W3TAG39
CAS number
75558-90-6
Weight
Average: 401.4927
Monoisotopic: 401.227868975
Chemical Formula
C23H29F2N3O
InChI Key
NNAIYOXJNVGUOM-UHFFFAOYSA-N
InChI
InChI=1S/C23H29F2N3O/c1-2-26-23(29)28-16-14-27(15-17-28)13-3-4-22(18-5-9-20(24)10-6-18)19-7-11-21(25)12-8-19/h5-12,22H,2-4,13-17H2,1H3,(H,26,29)
IUPAC Name
4-[4,4-bis(4-fluorophenyl)butyl]-N-ethylpiperazine-1-carboxamide
SMILES
[H]N(CC)C(=O)N1CCN(CCCC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)CC1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 2A
antagonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineAmperozide may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineAmperozide may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineAmperozide may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Amperozide.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Amperozide.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Amperozide.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Amperozide.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Amperozide.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Amperozide is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Amperozide is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Amperozide.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Amperozide is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Amperozide.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Amperozide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Amperozide is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Amperozide.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amperozide is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amperozide is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Amperozide.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amperozide is combined with Amoxapine.Approved
AmphetamineAmperozide may decrease the stimulatory activities of Amphetamine.Approved, Illicit
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Amperozide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Amperozide is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Amperozide.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Amperozide is combined with Azaperone.Investigational, Vet Approved
AzelastineAmperozide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Amperozide is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Amperozide.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Amperozide is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Amperozide.Approved
BenzphetamineAmperozide may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Amperozide.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Amperozide is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Amperozide.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Amperozide is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Amperozide.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Amperozide is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Amperozide is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Amperozide is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Amperozide.Approved, Investigational
BuprenorphineAmperozide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Amperozide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Amperozide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Amperozide is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Amperozide is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Amperozide is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Amperozide.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Amperozide.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Amperozide.Approved
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Amperozide.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amperozide.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Amperozide is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Amperozide.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Amperozide is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Amperozide is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Amperozide.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Amperozide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Amperozide.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amperozide.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Amperozide is combined with Chlorphenamine.Approved
ChlorphentermineAmperozide may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Amperozide.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amperozide.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Amperozide is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Amperozide.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Amperozide.Approved
ClemastineThe risk or severity of adverse effects can be increased when Amperozide is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Amperozide is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Amperozide is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Amperozide.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Amperozide is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Amperozide is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Amperozide is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Amperozide is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Amperozide.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Amperozide is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Amperozide.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Amperozide.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Amperozide.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Amperozide is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amperozide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Amperozide is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Amperozide is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Amperozide.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Amperozide is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Amperozide.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Amperozide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Amperozide is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Amperozide is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Amperozide.Approved
DetomidineThe risk or severity of adverse effects can be increased when Amperozide is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Amperozide is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Amperozide.Approved, Vet Approved
DextroamphetamineAmperozide may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Amperozide.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Amperozide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Amperozide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Amperozide.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Amperozide.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Amperozide is combined with Diethyl ether.Experimental
DiethylpropionAmperozide may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Amperozide is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Amperozide.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amperozide.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Amperozide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Amperozide.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Amperozide is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Amperozide.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Amperozide.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Amperozide is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Amperozide is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Amperozide is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Amperozide.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Amperozide.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Amperozide.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Amperozide.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Amperozide.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Amperozide is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Amperozide is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Amperozide.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Amperozide is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Amperozide.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Amperozide is combined with Entacapone.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Amperozide.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Amperozide.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Amperozide.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Amperozide.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Amperozide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Amperozide.Approved
EthanolAmperozide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Amperozide.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Amperozide is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Amperozide is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Amperozide.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Amperozide is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Amperozide.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Amperozide.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Amperozide is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Amperozide is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Amperozide is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Amperozide.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Amperozide is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Amperozide.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Amperozide is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Amperozide is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Amperozide.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Amperozide.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Amperozide is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Amperozide is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Amperozide is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Amperozide.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Amperozide is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Amperozide.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Amperozide.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Amperozide.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Amperozide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Amperozide.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Amperozide.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Amperozide is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amperozide.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Amperozide is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Amperozide.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Amperozide.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Amperozide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Amperozide is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Amperozide.Approved, Illicit, Investigational
GepefrineAmperozide may decrease the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Amperozide is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Amperozide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Amperozide is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Amperozide.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amperozide.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Amperozide.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Amperozide.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Amperozide.Approved
HydrocodoneAmperozide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Amperozide.Approved, Illicit
HydroxyamphetamineAmperozide may decrease the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Amperozide is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Amperozide is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Amperozide is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Amperozide is combined with Indiplon.Investigational
Iofetamine I-123Amperozide may decrease the stimulatory activities of Iofetamine I-123.Approved
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Amperozide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Amperozide.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Amperozide.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Amperozide.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Amperozide.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Amperozide is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Amperozide is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Amperozide.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Amperozide is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Amperozide is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Amperozide is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Amperozide.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Amperozide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Amperozide.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Amperozide.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Amperozide.Approved, Investigational
LisdexamfetamineAmperozide may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Amperozide.Approved
LofentanilThe risk or severity of adverse effects can be increased when Amperozide is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Amperozide is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Amperozide is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Amperozide.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Amperozide.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Amperozide is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Amperozide.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Amperozide.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Amperozide is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Amperozide is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Amperozide is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Amperozide is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Amperozide is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Amperozide.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Amperozide is combined with Melperone.Approved, Investigational
MephedroneAmperozide may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineAmperozide may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Amperozide.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amperozide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Amperozide is combined with Meptazinol.Experimental
MequitazineAmperozide may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Amperozide.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Amperozide is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Amperozide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Amperozide.Approved, Illicit
MethamphetamineAmperozide may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amperozide.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Amperozide.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Amperozide is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Amperozide.Approved
MethotrimeprazineAmperozide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Amperozide.Approved, Investigational, Vet Approved
MethoxyphenamineAmperozide may decrease the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Amperozide is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Amperozide.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Amperozide is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Amperozide.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amperozide.Approved, Investigational
MetyrosineAmperozide may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Amperozide.Approved, Illicit
MidomafetamineAmperozide may decrease the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Amperozide.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Approved, Investigational
MirtazapineAmperozide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAAmperozide may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Amperozide.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Amperozide.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Amperozide.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Amperozide.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Amperozide.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Amperozide.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Amperozide.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Amperozide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Amperozide is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Amperozide is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Amperozide is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Amperozide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Amperozide is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Amperozide.Approved
OpiumThe risk or severity of adverse effects can be increased when Amperozide is combined with Opium.Approved, Illicit
OrphenadrineAmperozide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Amperozide.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amperozide.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Amperozide is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Amperozide.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Amperozide.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Amperozide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Amperozide.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Amperozide.Approved
ParaldehydeAmperozide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Amperozide.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Amperozide is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Amperozide.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Amperozide.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Approved
PerazineThe risk or severity of adverse effects can be increased when Amperozide is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Amperozide.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Amperozide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Amperozide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Amperozide is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Amperozide.Approved
PhenibutThe risk or severity of adverse effects can be increased when Amperozide is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Amperozide.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Amperozide is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Amperozide is combined with Phenoxyethanol.Approved
PhentermineAmperozide may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Amperozide is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Amperozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Amperozide is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Amperozide is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Amperozide is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Amperozide is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Amperozide is combined with Pomalidomide.Approved
PramipexoleAmperozide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Amperozide is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Amperozide.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Amperozide.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Amperozide.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Amperozide is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Amperozide.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Amperozide.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amperozide.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Amperozide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Amperozide is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Amperozide is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Amperozide.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Amperozide.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Amperozide is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Amperozide is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Amperozide is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Amperozide.Investigational
PseudoephedrineAmperozide may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Amperozide.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Amperozide.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Amperozide.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Amperozide is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Amperozide is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Amperozide is combined with Ramelteon.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Amperozide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Amperozide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Amperozide.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Amperozide.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Amperozide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Amperozide is combined with Ritanserin.Investigational
RitobegronAmperozide may decrease the stimulatory activities of Ritobegron.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Amperozide.Approved
RomifidineThe risk or severity of adverse effects can be increased when Amperozide is combined with Romifidine.Vet Approved
RopiniroleAmperozide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Amperozide.Approved
RotigotineAmperozide may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Amperozide.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Amperozide is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Amperozide.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Amperozide.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Amperozide is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Amperozide.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Amperozide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amperozide.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Approved
StiripentolThe risk or severity of adverse effects can be increased when Amperozide is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amperozide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Amperozide is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Amperozide is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Amperozide.Approved, Investigational
SuvorexantAmperozide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Amperozide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Amperozide is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Amperozide.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Amperozide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Amperozide.Approved
TetracaineThe risk or severity of adverse effects can be increased when Amperozide is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Amperozide is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Amperozide.Investigational
ThalidomideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Amperozide.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Amperozide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Amperozide.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Amperozide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Amperozide is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Amperozide is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Amperozide is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Amperozide is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Amperozide is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Amperozide is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Amperozide is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Amperozide.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Amperozide.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amperozide.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Amperozide.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Amperozide.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Amperozide is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Amperozide is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Amperozide.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Amperozide is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Amperozide.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Amperozide is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Amperozide is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Amperozide.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Amperozide.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Amperozide.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Amperozide is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Amperozide is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Amperozide.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Amperozide is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Amperozide is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Amperozide is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Amperozide is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Amperozide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Amperozide is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Amperozide is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Amperozide.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Amperozide is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Amperozide.Approved, Investigational
ZolpidemAmperozide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Amperozide is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Amperozide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Amperozide is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Amperozide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Svartengren J, Simonsson P: Receptor binding properties of amperozide. Pharmacol Toxicol. 1990;66 Suppl 1:8-11. [PubMed:2154737]
  2. Meltzer HY, Zhang Y, Stockmeier CA: Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action. Eur J Pharmacol. 1992 May 27;216(1):67-71. [PubMed:1388121]
  3. Eriksson E: Amperozide, a putative anti-psychotic drug: uptake inhibition and release of dopamine in vitro in the rat brain. Life Sci. 1990;47(23):2111-7. [PubMed:1979998]
  4. Yamamoto BK, Meltzer HY: The effect of the atypical antipsychotic drug, amperozide, on carrier-mediated striatal dopamine release measured in vivo. J Pharmacol Exp Ther. 1992 Oct;263(1):180-5. [PubMed:1403783]
  5. Grenhoff J, Tung CS, Ugedo L, Svensson TH: Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol Toxicol. 1990;66 Suppl 1:29-33. [PubMed:2304893]
  6. Axelsson R, Nilsson A, Christensson E, Bjork A: Effects of amperozide in schizophrenia. An open study of a potent 5-HT2 receptor antagonist. Psychopharmacology (Berl). 1991;104(3):287-92. [PubMed:1924636]
  7. Kyriakis SC, Martinsson K, Olsson NG, Bjork A: Thin sow syndrome (TSS): the effect of amperozide. Br Vet J. 1990 Sep-Oct;146(5):463-7. [PubMed:2224491]
  8. Kyriakis SC, Olsson NG, Martinsson K, Bjork AK: Observations on the action of amperozide: are there social influences on sow-litter productivity? Res Vet Sci. 1991 Sep;51(2):169-73. [PubMed:1788479]
  9. Papp I, Waller C, Biro O: [Practical experiences in the therapy of postweaning edema disease in piglets]. Berl Munch Tierarztl Wochenschr. 1996 Oct;109(10):385-7. [PubMed:8999770]
External Links
PubChem Compound
73333
PubChem Substance
175427159
ChemSpider
66062
BindingDB
50311786
ChEBI
92913
ChEMBL
CHEMBL1079935
Wikipedia
Amperozide

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP4.12ChemAxon
pKa (Strongest Acidic)15.61ChemAxon
pKa (Strongest Basic)7.56ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area35.58 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity112.28 m3·mol-1ChemAxon
Polarizability43.52 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Phenylbutylamines / Piperazine carboxamides / N-alkylpiperazines / Fluorobenzenes / Aralkylamines / Aryl fluorides / Ureas / Trialkylamines / Azacyclic compounds / Organopnictogen compounds
show 4 more
Substituents
Diphenylmethane / Phenylbutylamine / Piperazine-1-carboxamide / Fluorobenzene / Halobenzene / N-alkylpiperazine / Aralkylamine / Aryl halide / 1,4-diazinane / Piperazine
show 19 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Svartengren J, Simonsson P: Receptor binding properties of amperozide. Pharmacol Toxicol. 1990;66 Suppl 1:8-11. [PubMed:2154737]

Drug created on October 08, 2013 14:39 / Updated on December 01, 2017 16:11